29 April 2019
Polycystic liver disease is the most common extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Grants for heart and kidney research Two awards to Radboudumc in Open Competition ENW-XS
21 July 2022Two researchers from the Radboudumc receive a grant from the NWO within the Open Competition of the Exact and Natural Sciences. They are Thijs Eijsvogels, who studies the heart, and Pieter Leermakers, who studies the kidneys.
read more
Grants for research on magnesium deficiency and malaria Vidis for Felix Hol and Jeroen de Baaij
1 July 2022 Radboudumc researchers Jeroen de Baaij and Felix Hol both receive an NWO Vidi grant for their research, respectively on magnesium deficiency in type 2 diabetes and on malaria. read more
Vote for the Supervisor of the year
12 December 2019 Deadline for voting is closed. The three nominated finalists are: Joost Drenth, Marien de Jonge and Iris Nagtegaal. read more
Response to treatment of Autoimmune Hepatitis
6 December 2019 Simon Pape and Joost Drenth published in Clinial Gastroenterology and Hepatology that a rapid response to treatment associates with normalization of transaminase levels in patients with Autoimmune Hepatitis. read more